TRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedDC
Delos Capital
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $58M 2 disclosed · full round size, not this investor’s share